A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf
.
Table of Contents
2012
Clinical Ovarian and Other Gynecologic Cancer
Effective treatment options for patients with ovarian cancer whose disease relapses or progresses within 6 months of initial therapy are limited. In the current open-label phase II study, 112 patients whose disease relapsed during or within 6 months after completion of platinum-based therapy received the novel microtubuletargeting agent patupilone. Patupilone was well tolerated and demonstrated promising efficacy in this difficultto-treat population. 60 Improved 8 -Year Survival for Patients
doi:10.1016/s2212-9553(14)00007-6
fatcat:rfx5f2gtxrg6den7c3vxzq355q